To investigate the difference between doublet and triplet neoadjuvant chemotherapy (NAC) regimens in efficacy and safety profile. Methods: A total of 227 locally advanced gastric cancer (LAGC) patients who received NAC and sequential radical gastrectomy were reviewed. After propensity score matching (PSM), 140 patients with similar baseline characteristics were selected. | Chen et al. BMC Cancer 2021 21 1328 https s12885-021-09093-9 RESEARCH Open Access Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer a propensity score matching analysis Yonghe Chen1 2 Jiasheng He1 2 Dan Liu3 Jian Xiao4 Xijie Chen1 2 Haijie Tang4 2 Dandong Luo1 2 Chenyu Shang3 Lei Lian1 2 and Junsheng Peng1 2 Abstract Background To investigate the differences between doublet and triplet neoadjuvant chemotherapy NAC regi- mens in efficacy and safety profile. Methods A total of 227 locally advanced gastric cancer LAGC patients who received NAC and sequential radical gastrectomy were reviewed. After propensity score matching PSM 140 patients with similar baseline characteristics were selected. Among them 70 received doublet NAC regimens consisted of platinum and fluorouracil the other 70 received triplet NAC regimens consisted of docetaxel platinum and fluorouracil. Results The efficacy of doublet and triplet regimens was comparable after propensity score matching in terms of tumor regression pathological complete response Doublet vs. Triplet p achieving of R0 resection Doublet vs. Triplet p 1 1-year disease-free survival DFS Doublet vs. Triplet p 3-years overall survival OS Doublet vs. Triplet p . Post-surgery complications were more common in the triplet cohort Doublet vs. Triplet p especially abdominal infection Dou- blet 0 vs. Triplet p . Conclusions A more intense preoperative triplet NAC regimen does not bring extra downstage effect and survival benefit compared to a doublet regimen. It may even result in a higher risk of post-surgery complications. Keywords Gastric cancer Neoadjuvant chemotherapy Survival Propensity score matching Background LAGC neoadjuvant chemotherapy NAC is recom- Gastric cancer is the fifth most common malignancy mended. However the recommended regimens vary globally and the third leading cause of .
